Altimmune Inc (ALT.OQ)
0.70USD
8:15pm IST
$0.00 (+0.57%)
$0.70
$0.70
$0.70
$0.69
13,800
46,141
$8.00
$0.65
Tue, Mar 27 2018
BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine
* ALTIMMUNE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE AND PROVIDES AN UPDATE ON ITS PHASE 1B STUDY OF HEPTCELL TARGETED IMMUNOTHERAPY IN CHRONIC HEPATITIS B INFECTION
BRIEF-Altimmune Announces Pre-Clinical Data From Its Sparvax-L Anthrax Vaccine Program
* ALTIMMUNE ANNOUNCES PRE-CLINICAL DATA FROM ITS SPARVAX-L ANTHRAX VACCINE PROGRAM
BRIEF-Hudson Bay Capital Management Reports A 9.99 Percent Passive Stake In Altimmune
* HUDSON BAY CAPITAL MANAGEMENT LP REPORTS A 9.99 PERCENT PASSIVE STAKE IN ALTIMMUNE, INC AS OF DECEMBER 31, 2017 - SEC FILING Source text for Eikon: [http://bit.ly/2nwUAiB] Further company coverage:
BRIEF-Altimmune Announces Allowance On Patent Covering Use Of Nasoshield In U.S.
* ALTIMMUNE ANNOUNCES NOTICE OF ALLOWANCE ON PATENT COVERING USE OF NASOSHIELD IN THE U.S. Source text for Eikon: Further company coverage:
BRIEF-Altimmune Elects Mitchel Sayare As Chairman Of Its Board
* ALTIMMUNE ELECTS MITCHEL SAYARE, PH.D. AS CHAIRMAN OF ITS BOARD OF DIRECTORS
BRIEF-Altimmune reports Q3 loss per share $2.05
* Altimmune announces third quarter 2017 financial results and provides corporate update
- Altimmune (ALT) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
- Altimmune's (ALT) CEO Bill Enright on Q4 2017 Results - Earnings Call Transcript
- Altimmune (ALT) Presents At Noble Financial Capital Markets 14th Annual Investor Conference - Slideshow
- Your Daily Pharma Scoop: ChemoCentryx Surges, Akebia Gets Positive News, Atara Prices Public Offering
- Your Daily Pharma Scoop: Ardelyx Reports Data, Omeros Moves Forward With OMS721, Allergan Announces Job Cuts
- Your Daily Pharma Scoop: Heron Enters 2018 On Strong Note, Teva Launches Generic Reyataz, Sarepta Top Smid-Cap Pick